Encompass Health
Provides intensive inpatient rehabilitation through a nationwide hospital network.
Something off on this page? Send us feedback.
Profile
Provides facility-based rehabilitation for patients recovering from major injuries and illnesses through a U.S. hospital network. Revenue comes mainly from reimbursed inpatient care, while standardized clinical protocols and joint-venture expansion define the operating model.
Provides intensive, facility-based rehabilitation for patients recovering from neurological, orthopedic, cardiac, pulmonary and other serious conditions. The focused portfolio consists of inpatient rehabilitation hospitals across the United States and Puerto Rico.
Care combines therapy, frequent physician visits and continuous nursing oversight under standardized clinical protocols. Growth comes through new hospitals, licensed-bed additions, acquisitions and joint ventures with acute-care hospitals and health systems.
Revenue is generated primarily from reimbursed inpatient care. Medicare and Medicare Advantage supply most revenue, alongside managed-care insurers, Medicaid and patients. Operations depend on reimbursement rules, quality standards, referral access, clinical staffing and joint-venture relationships.
Company facts
Key statistics
Year to date +13.6% · Average volume (30d) 900.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Truist Financial | Target | $140 | $150 | |
| Aug 7, 2026 | UBS | Reiterate | Buy | $150 | $155 |
| Aug 6, 2026 | Barclays | Reiterate | Overweight | $140 | $144 |
| May 22, 2026 | Leerink Partners | Target | $152 | ||
| May 5, 2026 | Barclays | Reiterate | Overweight | $153 | $140 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $1.48 | $1.55 | +4.7% | $1.57B | $1.60B | +1.7% | +12.55% |
| Apr 30, 2026Q1 FY26 | $1.51 | $1.60 | +6.0% | $1.57B | $1.59B | +1.2% | +7.48% |
| Feb 5, 2026Q4 FY25 | $1.29 | $1.46 | +13.2% | $1.54B | $1.54B | +0.3% | +5.86% |
| Oct 29, 2025Q3 FY25 | $1.19 | $1.23 | +3.4% | $1.54B | $1.48B | −4.1% | −7.02% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.46B | $1.46B | $1.48B | $1.54B | $1.59B | $1.60B | |
| Gross profit | $630.9M | $626.9M | $692.7M | $1.48B | $768.5M | $1.60B | |
| Operating income | $267.0M | $259.1M | $243.6M | $283.4M | $301.6M | $288.4M | |
| Net income | $151.5M | $142.1M | $126.5M | $146.1M | $194.5M | $153.9M | |
| Diluted EPS | $1.48 | $1.39 | $1.24 | $1.43 | $1.93 | $1.54 | |
| Gross margin | 43.3% | 43.0% | 46.9% | 95.8% | 48.4% | 100.0% | |
| Operating margin | 18.3% | 17.8% | 16.5% | 18.3% | 19.0% | 18.1% |
Fiscal years (4-quarter sums)FY21 $4.85B · FY22 $4.35B · FY23 $4.80B · FY24 $5.37B · FY25 $5.94B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $107.7M · Total debt $2.84B · Total assets $7.46B · Shareholders' equity $2.60B
Dividends
Raised for 2 straight years — most recently to $0.19 from $0.17 in Oct 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 1, 2026 | Jul 1 | Jul 15 | $0.19 | |
| Apr 1, 2026 | Apr 1 | Apr 15 | $0.19 | |
| Jan 2, 2026 | Jan 2 | Jan 15 | $0.19 | |
| Oct 1, 2025 | Oct 1 | Oct 15 | $0.19 | raised from $0.17 |
| Jul 1, 2025 | Jul 1 | Jul 15 | $0.17 | |
| Apr 1, 2025 | Apr 1 | Apr 15 | $0.17 | |
| Jan 2, 2025 | Jan 2 | Jan 15 | $0.17 | |
| Oct 1, 2024 | Oct 1 | Oct 15 | $0.17 | raised from $0.15 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 99.20M · Float 97.92M · 98.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.48M | 10.57% | 13F | Aug 7, 2026 |
| T. Rowe Price Associates, Inc. | 5.06M | 5.10% | 13G | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 5.06M | 5.10% | 13F | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 4.92M | 4.96% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.48M | 4.51% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 10, 2026 | John Patrick Darby | officer: EVP, Gen Counsel & Secretary | −8,906 | $125.95 |
| Aug 10, 2026 | Mark J. Tarr | director, officer: President & CEO | −173,148 | $125.47 |
| Aug 10, 2026 | Douglas E. Coltharp | officer: EVP & Chief Financial Officer | −18,869 | $125.38 |
| May 15, 2026 | Douglas E. Coltharp | officer: EVP & Chief Financial Officer | −27,694 | $106.83 |
| May 11, 2026 | Patrick William Tuer | officer: EVP, Chief Operating Officer | −682 | $104.56 |
Peers
- HCA Healthcare
Acute-care rehabilitation network competing for referrals and IRF patients
- Universal Health Services
Acute-care rehabilitation units contesting local IRF referrals
- The Ensign Group
Skilled-nursing substitute for less-intensive post-acute rehabilitation
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Encompass Health | $120.85 | 0.00% | $11.99B | 19.7 | 18.9 | 1.9 | +9.6% |
| HCA Healthcare | $417.82 | −0.00% | $90.46B | 14.0 | 13.6 | 1.2 | +8.7% |
| Universal Health Services | $172.00 | +0.09% | $10.39B | 7.0 | 7.4 | 0.6 | +8.3% |
| The Ensign Group | $172.98 | +0.01% | $10.08B | 27.1 | 21.2 | 1.8 | +17.3% |
| Median | 14.0 | 13.6 | 1.2 | +8.7% |